European Commission approves Johnson & Johnson's TECVAYLI monotherapy for relapsed multiple myeloma
FROM THE WIRE · MANILATIMES.NET
Approval is based on Phase 3 results demonstrating significant progression-free and overall survival benefits, with teclistamab reducing risk of disease progression or death by 71% and risk of death by 40%, compared with the standard of care1Further expands treatment options for…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishThe approval expands J&J's treatment options in a key therapeutic area, supported by progression-free and overall survival benefits.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01The European Commission approved the indication extension of TECVAYLI as monotherapy.
- 02The indication covers adult patients with relapsed or refractory multiple myeloma who have had at least one prior therapy.
- 03Phase 3 data show a 71% reduction in the risk of progression or death.
- 04The risk of death was reduced by 40% compared with the standard of care.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets